Findings from Fox Chase Cancer Center Has Provided New Information about DNA Research (DUSP6 regulates drug sensitivity by modulating DNA damage response)
By a News Reporter-Staff News Editor at Biotech Week -- Current study results on DNA Research have been published. According to news originating from Philadelphia, Pennsylvania, by NewsRx correspondents, research stated, "Dual specificity phosphatase 6 (DUSP6) is a member of a family of mitogen-activated protein kinase phosphatases that dephosphorylates and inhibits activated ERK1/2. Dual specificity phosphatase 6 is dynamically regulated in developmental and pathological conditions such as cancer."
Our news journalists obtained a quote from the research from Fox Chase Cancer Center, "Cancer cell lines were made deficient in DUSP6 by siRNA and shRNA silencing. Sensitivity to anti-EGFR and chemotherapeutic agents was determined in viability and apoptosis assays, and in xenografts established in SCID mice. Cellular effects of DUSP6 inactivation were analysed by proteomic methods, followed by analysis of markers of DNA damage response (DDR) and cell cycle. We determined that depletion of DUSP6 reduced the viability of cancer cell lines and increased the cytotoxicity of EGFR and other targeted inhibitors, and cytotoxic agents, in vitro and in vivo. Subsequent phosphoproteomic analysis indicated DUSP6 depletion significantly activated CHEK2 and p38, which function in the DDR pathway, and elevated levels of phosphorylated H2AX, ATM, and CHEK2, for the first time identifying a role for DUSP6 in regulating DDR."
According to the news editors, the research concluded: "Our results provide a novel insight into the DUSP6 function in regulating genomic integrity and sensitivity to chemotherapy in cancer."
For more information on this research see: DUSP6 regulates drug sensitivity by modulating DNA damage response. British Journal of Cancer, 2013;109(4):1063-71. (Nature Publishing Group - www.nature.com/; British Journal of Cancer - www.nature.com/bjc/)
The news correspondents report that additional information may be obtained from T.V. Bagnyukova, Program in Developmental Therapeutics, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, United States. Additional authors for this research include D. Restifo, N. Beeharry, L. Gabitova, T. Li, I.G. Serebriiskii, E.A. Golemis and I. Astsaturov (see also DNA Research).
Keywords for this news article include: Philadelphia, Pennsylvania, United States, North and Central America, Cancer, DNA Damage, DNA Research, Deoxyribonucleic Acid, Genetics, Oncology, Proteomics.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC